# Cerus Corp (CERS)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/cerus-corp/ JSON: https://steadybase.io/company/cerus-corp.json Checked Nov 10, 2026. Latest filing read: Nov 2, 2026.

## Company

- Legal name: CERUS CORP
- Ticker: CERS (Nasdaq)
- SEC CIK: 0001020214
- Industry: Surgical & Medical Instruments & Apparatus (SIC 3841)
- Headquarters: Concord, CA
- Fiscal year ends: December 31
- SEC filer category: Accelerated filer
- Website: cerus.com
- LinkedIn: https://www.linkedin.com/company/cerus
- Next earnings date: Jan 8, 2027 (estimated from past 8-K timing)

## Key facts

- Revenue: $233.8M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 2, 2026). Source: https://www.sec.gov/Archives/edgar/data/1020214/000119312526085678/0001193125-26-085678-index.html
- Operating income: -$8.7M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 2, 2026). Source: https://www.sec.gov/Archives/edgar/data/1020214/000119312526085678/0001193125-26-085678-index.html
- Net income: -$15.6M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 2, 2026). Source: https://www.sec.gov/Archives/edgar/data/1020214/000119312526085678/0001193125-26-085678-index.html
- SG&A: $80.9M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 2, 2026). Source: https://www.sec.gov/Archives/edgar/data/1020214/000119312526085678/0001193125-26-085678-index.html
- Employees: 275 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1020214/000119312526085678/cers-20251231.htm
- Shares outstanding: 201,954,184 as of Oct 16, 2026 (10-Q filed Nov 2, 2026). Source: https://www.sec.gov/Archives/edgar/data/1020214/000119312526443694/0001193125-26-443694-index.html
- Auditor: Ernst & Young LLP, San Francisco, California, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1020214/000119312526085678/cers-20251231.htm

## Business

We are a biomedical products company focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on our proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1020214/000119312526085678/cers-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $233.8M | -$8.7M | -$15.6M | $80.9M |
| Dec 31, 2024 | $201.3M | -$14.2M | -$20.9M | $75.9M |
| Dec 31, 2023 | $186.8M | -$30.1M | -$37.5M | $75.5M |
| Dec 31, 2022 | $188.3M | -$34.1M | -$42.8M | $83.3M |
| Dec 31, 2021 | $159.5M | -$48.9M | -$54.4M | $81.3M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/cerus-corp.json

## Officers and directors

- Vivek Jayaraman, Cerus’s president and chief executive officer. Source: 8-K filed Nov 2, 2026, https://www.sec.gov/Archives/edgar/data/1020214/000119312526443646/cers-ex99_1.htm
- Vivek K. Jayaraman, Chief Executive Officer. LinkedIn: https://linkedin.com/in/vkjayaraman. Source: Form 4 filed Jul 20, 2026, https://www.sec.gov/Archives/edgar/data/1020214/000119312526309044/0001193125-26-309044-index.htm
- William Mariner Greenman, President and CEO. Source: Form 4 filed Jul 2, 2026, https://www.sec.gov/Archives/edgar/data/1020214/000137725826000008/0001377258-26-000008-index.htm
- Kevin Dennis Green, Chief Financial Officer. Source: Form 4 filed Jul 2, 2026, https://www.sec.gov/Archives/edgar/data/1020214/000145935126000011/0001459351-26-000011-index.htm
- Kevin D. Green, Vice President, Finance and Chief Financial Officer. LinkedIn: https://www.linkedin.com/in/kevin-green-3482221. Source: 10-K filed Mar 2, 2026, https://www.sec.gov/Archives/edgar/data/1020214/000119312526085678/cers-20251231.htm
- Chrystal Jensen, Chief Legal Officer. Source: Form 4 filed Aug 17, 2026, https://www.sec.gov/Archives/edgar/data/1020214/000119312526354496/0001193125-26-354496-index.htm
- Richard J. Benjamin, Chief Medical Officer. Source: Form 4 filed Mar 16, 2026, https://www.sec.gov/Archives/edgar/data/1020214/000129632226000009/0001296322-26-000009-index.htm
- Ann Lucena, Director. Source: 10-K filed Mar 2, 2026, https://www.sec.gov/Archives/edgar/data/1020214/000119312526085678/cers-20251231.htm
- Dean A. Gregory, Director. Source: 10-K filed Mar 2, 2026, https://www.sec.gov/Archives/edgar/data/1020214/000119312526085678/cers-20251231.htm
- Eric H. Bjerkholt, Director. Source: 10-K filed Mar 2, 2026, https://www.sec.gov/Archives/edgar/data/1020214/000119312526085678/cers-20251231.htm
- Frank Witney, Ph.D., Director. Source: 10-K filed Mar 2, 2026, https://www.sec.gov/Archives/edgar/data/1020214/000119312526085678/cers-20251231.htm
- Jami Nachtsheim, Director. Source: 10-K filed Mar 2, 2026, https://www.sec.gov/Archives/edgar/data/1020214/000119312526085678/cers-20251231.htm
- Timothy L. Moore, Director. Source: 10-K filed Mar 2, 2026, https://www.sec.gov/Archives/edgar/data/1020214/000119312526085678/cers-20251231.htm
- Richard Benjamin, Named in proxy. Source: DEF 14A filed Apr 22, 2026, https://www.sec.gov/Archives/edgar/data/1020214/000102021426000011/cers-20260422.htm

## Recent 8-K events

- Nov 2, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1020214/000119312526443646/cers-20261102.htm
- Jul 30, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1020214/000119312526326093/cers-20260730.htm
- Jul 10, 2026: Item 5.02, Departure or appointment of directors or officers; compensation. Source: https://www.sec.gov/Archives/edgar/data/1020214/000102021426000015/cers-20260706.htm
- Jun 8, 2026: Item 1.01, Entry into a material definitive agreement; Item 1.02, Termination of a material definitive agreement; Item 2.03, Creation of a direct financial obligation. Source: https://www.sec.gov/Archives/edgar/data/1020214/000119312526261794/cers-20260605.htm
- Jun 3, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/1020214/000119312526255488/cers-20260602.htm
- Apr 30, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1020214/000119312526197129/cers-20260430.htm
- Apr 21, 2026: Item 5.02, Departure or appointment of directors or officers; compensation. Source: https://www.sec.gov/Archives/edgar/data/1020214/000102021426000007/cers-20260417.htm
- Mar 16, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1020214/000119312526108629/cers-20260311.htm
- Mar 2, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1020214/000119312526085350/cers-20260302.htm
- Jan 23, 2026: Item 5.02, Departure or appointment of directors or officers; compensation. Source: https://www.sec.gov/Archives/edgar/data/1020214/000119312526021085/cers-20260119.htm

## Insider trades (Form 4)

- Aug 17, 2026: Chrystal Jensen (Chief Legal Officer) sold 30,000 shares, about $89,400. Source: https://www.sec.gov/Archives/edgar/data/1020214/000119312526354496/0001193125-26-354496-index.htm
- Jul 16, 2026: Vivek K. Jayaraman (Chief Executive Officer) sold 16,666 shares, about $52,665. Source: https://www.sec.gov/Archives/edgar/data/1020214/000119312526309044/0001193125-26-309044-index.htm
- Jun 30, 2026: Vivek K. Jayaraman (Chief Operating Officer) sold 42,359 shares, about $124,535. Source: https://www.sec.gov/Archives/edgar/data/1020214/000160545626000008/0001605456-26-000008-index.htm
- Jun 30, 2026: Chrystal Jensen (Chief Legal Officer) sold 24,329 shares, about $71,527. Source: https://www.sec.gov/Archives/edgar/data/1020214/000156425226000010/0001564252-26-000010-index.htm
- Jun 30, 2026: Kevin Dennis Green (Chief Financial Officer) sold 33,676 shares, about $99,007. Source: https://www.sec.gov/Archives/edgar/data/1020214/000145935126000011/0001459351-26-000011-index.htm
- Jun 30, 2026: William Mariner Greenman (President and CEO) sold 101,919 shares, about $299,642. Source: https://www.sec.gov/Archives/edgar/data/1020214/000137725826000008/0001377258-26-000008-index.htm
- Jun 9, 2026: Eric Bjerkholt (Director) sold 20,454 shares, about $53,180. Source: https://www.sec.gov/Archives/edgar/data/1020214/000119312526268227/0001193125-26-268227-index.htm
- May 29, 2026: Vivek K. Jayaraman (Chief Operating Officer) sold 16,667 shares, about $50,001. Source: https://www.sec.gov/Archives/edgar/data/1020214/000119312526254106/0001193125-26-254106-index.htm
- May 1, 2026: Vivek K. Jayaraman (Chief Operating Officer) sold 16,667 shares, about $50,001. Source: https://www.sec.gov/Archives/edgar/data/1020214/000119312526206993/0001193125-26-206993-index.htm
- Mar 12, 2026: Vivek K. Jayaraman (Chief Operating Officer) sold 165,200 shares, about $274,232. Source: https://www.sec.gov/Archives/edgar/data/1020214/000160545626000006/0001605456-26-000006-index.htm
- Mar 12, 2026: Kevin Dennis Green (Chief Financial Officer) sold 127,544 shares, about $211,723. Source: https://www.sec.gov/Archives/edgar/data/1020214/000145935126000007/0001459351-26-000007-index.htm
- Mar 12, 2026: William Mariner Greenman (President and CEO) sold 447,757 shares, about $743,277. Source: https://www.sec.gov/Archives/edgar/data/1020214/000137725826000006/0001377258-26-000006-index.htm
- Mar 12, 2026: Richard J. Benjamin (Chief Medical Officer) sold 101,740 shares, about $168,888. Source: https://www.sec.gov/Archives/edgar/data/1020214/000129632226000009/0001296322-26-000009-index.htm
- Mar 9, 2026: Richard J. Benjamin (Chief Medical Officer) sold 125,894 shares, about $250,853. Source: https://www.sec.gov/Archives/edgar/data/1020214/000129632226000004/0001296322-26-000004-index.htm
- Mar 6, 2026: Vivek K. Jayaraman (Chief Operating Officer) sold 34,094 shares, about $68,529. Source: https://www.sec.gov/Archives/edgar/data/1020214/000160545626000004/0001605456-26-000004-index.htm

## What management said

- "Our solid performance in Q3 builds upon a strong first half of 2026 and increases our confidence as we approach year-end" Vivek Jayaraman, Cerus’s president and chief executive officer (8-K filed Nov 2, 2026). Source: https://www.sec.gov/Archives/edgar/data/1020214/000119312526443646/cers-ex99_1.htm

## Latest filings

- 8-K filed Nov 2, 2026: https://www.sec.gov/Archives/edgar/data/1020214/000119312526443646/cers-20261102.htm
- 10-K filed Mar 2, 2026: https://www.sec.gov/Archives/edgar/data/1020214/000119312526085678/cers-20251231.htm
- 10-Q filed Nov 2, 2026: https://www.sec.gov/Archives/edgar/data/1020214/000119312526443694/cers-20260930.htm
- DEF 14A filed Apr 22, 2026: https://www.sec.gov/Archives/edgar/data/1020214/000102021426000011/cers-20260422.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/